Australian approval for Yourgene® DPYD Assay
![]()
Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)
Australian regulatory approval for Yourgene® Insight DPYD Assay
TGA approval extends commercial opportunity beyond research use to clinical diagnostic testing
Paris, France, and Manchester, UK – 11 November 2026 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a growing portfolio of integrated technologies and services, announces Australian regulatory approval for its Yourgene® Insight DPYD assay. The approval enables Southern Cross Diagnostics Pty Ltd, part of the Novacyt Group, to market and supply the in vitro diagnostic assay for its approved clinical diagnostic use in Australia, extending its commercial opportunity beyond research use only to clinical diagnostic testing.
The Therapeutic Goods Administration (TGA) has approved the supply of the Yourgene® Insight DPYD assay in Australia. The assay, manufactured by Yourgene Health, is covered by an Australian Register of Therapeutic Goods (ARTG) inclusion for Class 3 pharmacogenetic in vitro diagnostic devices (IVDs), held by Southern Cross Diagnostics as the Australian sponsor. It is also certified under the European Union’s In Vitro Diagnostic Regulation (IVDR).
The Yourgene® Insight DPYD assay detects 19 clinically relevant variants in the DPYD gene, supporting the identification of patients at increased risk of severe or potentially fatal toxicity in patients receiving 5-fluorouracil (5-FU) treatment. It provides laboratories and clinicians with information to support informed treatment decisions and improve patient management.
The Australian approval builds on the successful launch of the Yourgene® Insight DPYD assay as a Research Use Only (RUO) product in May 2026, followed by its certification under the IVDR in September 2026. TGA approval represents a further step in the product's international regulatory expansion, enabling access to another highly regulated market.
The Yourgene® Insight DPYD assay is the first CE-marked DPYD assay certified under IVDR to incorporate all current Tier 1 and Tier 2 variants recommended by both the Association for Molecular Pathology (AMP) and the National Comprehensive Cancer Network (NCCN). Developed in close collaboration with leading clinicians and subject to extensive evaluation, the assay provides a comprehensive testing solution designed to meet the requirements of routine clinical laboratories.
TGA approval further extends the commercial reach of the Yourgene® Insight DPYD assay, building on its regulatory credentials in Europe and creating additional opportunities to supply laboratories in Australia. The Company estimates that the addressable market for DPYD testing in Australia is approximately 16,000 to 66,000 tests per year. Based on the current Australian Medicare reimbursement of approximately A$182 per test, this represents a total annual reimbursed testing value to laboratories of approximately A$3.0 million to A$12.0 million.
Lyn Rees, Chief Executive Officer of Novacyt, commented: “Australian approval expands the commercial opportunity for our Yourgene® Insight DPYD assay into routine clinical testing. Through Southern Cross Diagnostics, we can now offer Australian laboratories a registered diagnostic assay to support the identification of patients at increased risk of severe chemotherapy toxicity.
“Following IVDR certification in September, this approval advances our international expansion and demonstrates how our Australian distribution business can bring products from across the Group to clinical customers. We can bring our established pharmacogenomics testing solution to a wider international customer base and supports our strategy to grow our clinical genetics business and broaden access to pharmacogenomic testing.”
Contacts
|
Novacyt SA |
||||
|
Lyn Rees, Chief Executive Officer |
Via Walbrook PR |
|||
|
Steve Gibson, Chief Financial Officer
|
|
|||
|
|
|
|||
|
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
+44 (0)20 3470 0470 |
|||
|
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
|
|||
|
|
|
|||
|
Singer Capital Markets (Joint Broker) |
+44 (0) 20 7496 3000 |
|||
|
Russell Cook / Graham Hertrich / James Fischer |
|
|||
|
|
|
|||
|
Inbound Capital – Listing Sponsor (Euronext Growth Paris) Frédéric Portier / Claire Barbaret |
fportier@inbound.capital / cbarbaret@inbound.capital
|
|||
|
|
|
|||
|
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / William Turner |
+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 020 470 |
|||

About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
|
Clinical |
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
|
|
Instrumentation |
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
|
|
Research Use Only |
Range of services for the life sciences industry:
|
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.
The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).
For more information, please refer to the website: www.novacyt.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE